KAS
CSTL icon

Kemnay Advisory Services’s Castle Biosciences CSTL Stock Holding History

Kemnay Advisory Services’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-889
Closed -$34.6K – 1221
2025
Q4 		$34.6K Buy
+889
New +$28.7K 0.01% 396

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kemnay Advisory Services's CSTL Position: Q1 2026 in Review

Kemnay Advisory Services sold out of Castle Biosciences (CSTL) in Q1 2026, closing a stake of 889 shares — an estimated $34.6K sold.

Kemnay Advisory Services first reported a position in CSTL in Q4 2025 and held it in 1 quarter. The position peaked at $34.6K in Q4 2025. 186 funds tracked by Wall St. Rank hold CSTL as of Q1 2026.

  • Kemnay Advisory Services reported no remaining Castle Biosciences position as of Q1 2026 after selling out during the quarter.
  • Kemnay Advisory Services sold 889 Castle Biosciences shares in Q1 2026, an estimated $34.6K.
  • Kemnay Advisory Services first reported a position in Castle Biosciences in Q4 2025 and held it in 1 quarter.
  • Kemnay Advisory Services's Castle Biosciences position peaked at $34.6K in Q4 2025.
  • 186 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2026.

Based on Kemnay Advisory Services's 13F filing for Q1 2026, filed 15 May 2026.